NCT06080620 The Choice of Treatment Methods and Efficacy of LABC
| NCT ID | NCT06080620 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Locally Advanced Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-10-08 |
| Primary Completion | 2025-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2023-10-08 with a primary completion date of 2025-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare the therapeutic effects of chemotherapy followed by surgery and surgery followed by chemotherapy in patients with locally advanced breast cancer（LABC). Patients with LABC will be randomly divided into two groups, each receiving chemotherapy followed by surgery or surgery followed by chemotherapy. The main comparison was between the disease-free survival (DFS) of two groups of patients, with the secondary study endpoint being overall survival (OS); Five year survival; Local recurrence or distant metastasis rate.
Eligibility Criteria
Inclusion Criteria: 1. 18-70 year old female 2. Patients with locally advanced breast cancer (stage IIIb - IIIc) first diagnosed; 3. Clinical diagnosis of breast cancer, or puncture pathology suggests breast cancer; 4. After evaluation by experienced clinical physicians, the patient's tumor has the possibility of surgical resection. Specific evaluation indicators include ultrasound assessment of the tumor not surrounding the axillary vein; 5. Accept treatment plans including surgery, radiotherapy, and chemotherapy; 6. Volunteer to participate in clinical research and sign an informed consent form; 7. Willing to undergo follow-up and complete quality of life (EQ-5D series scale and FACT-B scale) and postoperative psychological status (Anxiety/Depression Self Rating Scale) assessments; Exclusion Criteria: 1. Patients under 18 years old or over 70 years old; 2. Those who have received breast cancer related surgery, radiotherapy or chemotherapy; 3. Those who are not expected to receive surgery, radiotherapy or chemotherapy related to breast cancer 4. History of other malignant tumors; 5. Pregnant or lactating women; 6. Accompanying active infection and fever; 7. Other serious diseases that may significantly affect clinical trial compliance, such as severe cardiopulmonary dysfunction, liver and kidney dysfunction, poorly controlled diabetes and mental illness.
Contact & Investigator
Yan Lin
STUDY CHAIR
Peking Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT06080620 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 70 Years, studying Locally Advanced Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06080620 currently recruiting?
Yes, NCT06080620 is actively recruiting participants. Contact the research team at xuying@pumch.cn for enrollment information.
Where is the NCT06080620 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06080620 clinical trial?
NCT06080620 is sponsored by Peking Union Medical College Hospital. The principal investigator is Yan Lin at Peking Union Medical College Hospital. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.